Skip to content
Screener

Protagonist Therapeutics PTGX Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue$5.5MMiss by $2.9M
EPS-$0.55Miss by $0.02
Revenue estimate$8.4M
EPS estimate-$0.53

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$240.1M
EPS estimate$2.43

Financials

Q2 2025

Income statement

See full
Revenue$5.5M+33.1%
Operating income-$42.0M-8.4%
Net income-$34.8M-13.6%
EPS (diluted)-$0.55-10.0%

Balance sheet

See full
Cash & equivalents$168.5M-52.6%
Total debt$11.3M+2.8%
Total equity$668.0M+23.4%
Total assets$718.0M+16.8%

Cash flow

See full
CapEx$813.0K+2,804%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$3.33B+57.8%
Enterprise value$3.17B+79.7%
P/E63.9×—
P/S15.9×+9.3×

Profitability

See full
Operating margin11.5%—
Net margin24.9%—

Returns & leverage

See full
Return on equity8.6%—
Debt / equity0×0.0×
Current ratio17×+3.2×

FAQ

When did Protagonist Therapeutics report Q2 2025 earnings?
Protagonist Therapeutics (PTGX) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Protagonist Therapeutics's Q2 2025 revenue and EPS?
Protagonist Therapeutics reported revenue of $5.5M and eps of $-0.55 for Q2 2025.
Did Protagonist Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $8.4M by $2.9M. EPS missed the consensus estimate of $-0.53 by $0.02.
How did Protagonist Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.1% from $4.2M a year earlier and eps declined 10.0% from $-0.50.
Where can I find Protagonist Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-074719) and the 10-Q periodic report (0001558370-25-010534) directly on SEC EDGAR. The filing index links above go to sec.gov.